Chaperone therapy for neuronopathic lysosomal diseases: Competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities

Perspectives in Medicinal Chemistry

Volumn 2009, Issue 3, 2009, Pages 7-19

  Suzuki, Yoshiyuki ^a   Ogawa, Seiichiro ^b   Sakakibara, Yasubumi ^b  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Chaperone; Gaucher disease; Lysosomal disease; Lysosomal enzyme; Valienamine; galactosidase; glucosidase

Indexed keywords

BETA GALACTOSIDASE; CHAPERONE; GALACTOSYLCERAMIDASE; N OCTYL 4 EPI BETA VALIENAMINE; N OCTYL BETA VALIENAMINE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST CULTURE; GENE MUTATION; GM1 GANGLIOSIDOSIS; HUMAN; IC 50; LYSOSOME STORAGE DISEASE; MOLECULAR INTERACTION; NEURONOPATHIC LYSOSOMAL DISEASE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 77953386183     PISSN: None     EISSN: 1177391X     Source Type: Journal    
DOI: 10.4137/pmc.s2332     Document Type: Review

References (64)

1. De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol. 1966;28:435-92.
2. Hers HG. Inborn lysosomal disease. Gastroenterology. 1965;48:625-33.
3. Brady RO. Emerging strategies for the treatment of hereditary metabolic storage disorders. Rejuvenation Res. 2006;9:237-344.
4. M1-Gangliosidosis and Morquio B disease. In The Online Metabolic and Molecular Bases of Inherited Disease Chapter 151, Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SF, Ballabio A. eds. New York, McGraw-Hill, 2008; p. 1-101, http://www.ommbid.com/.
5. M1-gangliosidosis. Correlation of clinical and biochemical data. Arch Neurol. 1971; 24:58-64.
6. M1 in cultured skin fibroblasts and correlation with clinical types. Hum Genet. 1978;43:127-31.
7. M1-gangliosidosis: A complementation study on somatic cell hybrids. Brain Dev. 1979;1:83-6.
8. Ko YM, Yamanaka T, Umeda M, Suzuki Y. Effects of thiol protease inhibitors on intracellular degradation of exogenous β-galactosidase in cultured human skin fibroblasts. Exp Cell Res. 1983;148:525-9.
9. M1-gangliosidosis: abnormalities in biosynthesis and early processing of β-galactosidase in fibroblasts. Biochem Biophys Res Commun. 1988;152:794-800.
10. Oshima A, Tsuji A, Nagao Y, Sakuraba H, Suzuki Y. Cloning, sequencing, and expression of cDNA for human β-galactosidase. Biochem Biophys Res Commun. 1988;157:238-44.
11. Eng CM, Ioannou YA, Desnick RJ. α-Galactosidase A Deficiency: Fabry Disease. In The Online Metabolic and Molecular Bases of Inherited Disease Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SF, Ballabio A. eds. New York, McGraw-Hill, p. . 2008
12. Okumiya T, Ishii S, Takenaka T, et al. Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease. Biochem Biophys Res Commun. 1995;214:1219-24.
13. Fan JQ, Asano N, Suzuki Y, Ishii S. Chemical chaperone therapy for Fabry disease, a genetic disorder. Glycoconjugate J. 1999;16:S156.
14. M1-gangliosidosis. Proc Natl Acad Sci U S A. 2003;100:15912-7.
15. Lin H, Sugimoto Y, Ohsaki Y, et al. N-octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim Biophys Acta. 2004;1689:219-28.
16. Iwasaki H, Watanabe H, Iida M, et al. Fibroblast screening for chaperone therapy in β-galactosidosis. Brain Dev. 2006;28:482-6.
17. Suami T, Ogawa S. Chemistry of carba-sugars (pseudo-sugars) and their derivatives. Adv Carbohydr Chem Biochem. 1990;48:21-90.
18. Ogawa S. Synthesis studies on glycosidase inhibitors composed of 5a-carba-sugars. In: Carbohydrate Mimics, Y. Chapleur, ed. Weinheim, Wiley-VCH, 1998. p. 87-106.
19. Ogawa S. Design and synthesis of carba-sugars of biological interest. Trends Glycosci Glycotechnol. 2004;16:33-53.
20. McCasland GE, Stanley F, Lois JD. Alicyclic carbohydrates. XXIX. The synthesis of a pseudo-hexose (2,3,4,5-tetrahydroxycyclohexanemethanol). J Org Chem. 1966;31:1516-21.
21. Miller TW, Arison BH, Albers-Schonberg G. Isolation of a cyclic antibiotic: 2,3,4,5-tetrahydroxycyclohexanemethanol. Biotech Bioeng. 1973;15:1075-80.
22. Suami T, Ogawa S, Toyokuni T. Sweet tasting pseudo-sugars. Chem Lett. 1983;611-12.
23. Iwasa T, Yamamoto H, Shibata M. Studies on validamycins, new antibiotics. I. Streptomyces hygroscopicus var. limoneus nov. var., validamycin-producing organism. Jpn J Antibiot. 1970;23:595-602.
24. Horii S, Iwasa T, Mizuta E, Kameda Y. Studies on validamycins, new antibiotics. VI. Validamine, hydroxyvalidamine and validatol, new cyclitols. J Antibiot. 1971;24:59-63.
25. Kameda Y, Horii S. The unsaturated cyclitol part of the new antibiotics, the validamycins. J Chem Socy Chem Commun. 1972;746-7.
26. Schmidt DD, Frommer W, Junge B, et al. α-Glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften. 1977;64:535-36.
27. Junge B, Heiker FR, Kurz J, Muller L, Schmidt DD. Untersuchungen zur struktur des α-D-glucosdiase inhibitors acarbose. Carbohydrate Res. 1984;128:235-68.
28. Horii S, Fukase H, Matsuo T, Kameda Y, Asano N, Matsui K. Synthesis and α-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J Med Chem. 1986;29:1038-46.
29. Fukase H, Horii S. Synthesis of valiolamine and its N-substituted derivatives AO-128, validoxylamine-G, and validamycin-G via branched-chain inosose derivatives. J Org Chem. 1992;57:3651-8.
30. Ogawa S, Suetsugu M, Toyokuni T, Suami T. Synthesis of DL-6′-epivalidoxylamine A. Nippon Kagaku Kaishi. 1982; 1721-6.
31. Ogawa S, Uchida C, Shibata Y. Alternative synthesis and enzyme-inhibitory activity of methyl 1′-epiacarviosin and its 6-hydroxy analog. Carbohydr Res. 1992;223:279-86.
32. Lockhoff O. Glycolipids as immunomodulators: synthesis and properties. Angew Chem, Internatl Ed English. 1991;30:1611-20.
33. Tsunoda H, Ogawa S. Synthesis of some 5a-carbaglycosylamides, glycolipid analogs of biological interests. Liebigs Annal Chem. 1994;103-7.
34. Tsunoda H, Ogawa S. Synthesis of 5a-carba-β-D-glycosylceramide analogs linked by imino, ether and sulfi de bridges. Liebigs Annal Chem. 1995;267-77.
35. Tsunoda H, Inokuchi J, Yamagishi K, Ogawa S. Synthesis of glycosylceramide analogs composed of imino-linked unsaturated 5a-carbaglycosyl residues: potent and specific gluco- and galactocerebrosidase inhibitors. Liebigs Annal Chem. 1995;279-84.
36. Ogawa S, Ashiura M, Uchida C, et al. Synthesis of potent β-D-glucocerebrosidase inhibitors: N-alkyl-β-valienamines. Bioorg Med Chem Lett. 1996; 6:929-32.
37. Ogawa S, Sakata Y, Ito N, et al. Convenient synthesis and evaluation of glycosidase inhibitory activity of α- and β-galactose-type valienamines, and some N-alkyl derivatives. Bioorg Med Chem. 2004;12: 995-1002.
38. Ogawa S, Matsunaga YK, Suzuki Y. Chemical modification of the β-glucocerebrosidase inhibitor N-octyl-β-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(β-D-galactopyranosyl) derivatives. Bioorg Med Chem. 2002;10:1967-72.
39. Arjona O, Gomez AM, Lopez JC, Plumet J. Synthesis and conformational and biological aspects of carbasugars. Chem Rev. 2007;107: 1919-2036.
40. 3,7]nonan-5-one. J Chem Soc Perkin Trans. 1985; 1:903-6.
41. Ogawa S, Kobayashi Y, Kabayama K, Jimbo M, Inokuchi J. Chemical modifi cation of β-glucocerebrosidase inhibitor N-octyl-β-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives. Bioorg Med Chem. 1998; 6:1955-62.
42. Ogawa S, Asada M, Ooki Y, Mori M, Itoh M, Korenaga T. Design and synthesis of glycosidase inhibitor 5-amino-1,2,3,4-cyclohexanetetrol derivatives from (-)-vibo-quercitol. Bioorg Med Chem. 2005;13: 4306-14.
43. Ogawa S, Kanto M. Synthesis of valiolamine and some precursors for bioactive carbaglycosylamines from (-)-vibo-quercitol produced by biogenesis of myo-inositol. J Nat Prod. 2007;70:493-7.
44. Ogawa S, Kanto M, Suzuki Y. Development and medical application of unsaturated carbaglycosylamine glycosidase inhibitors. Mini Rev Med Chem. 2007;7:679-91.
45. M1-gangliosidosis: A common mutation among Japanese adult/chronic cases. Am J Hum Genet. 1991;49:435-42.
46. Oshima A, Yoshida K, Shimmoto M, Fukuhara Y, Sakuraba H, Suzuki Y. Human β-galactosidase gene mutations in Morquio B disease. Am J Hum Genet. 1991;49:1091-3.
47. Schiffmann R, Brady RO. New prospects for the treatment of lysosomal storage diseases. Drugs. 2002;62:733-42.
48. M1-gangliosidosis. Metab Brain Dis. 2008;23:161-73.
49. Suzuki Y. β-galactosidase deficiency: an approach to chaperone therapy. J Inherit Metab Dis. 2006;29:471-6.
50. Ishii S, Kase R, Sakuraba H, Suzuki Y. Characterization of a mutant α-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun. 1993;197:1585-9.
51. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med. 2001;345:25-32.
52. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5:112-5.
53. Tominaga L, Ogawa Y, Taniguchi M, et al. Galactonojirimycin derivatives restore mutant human β-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse. Brain Dev. 2001;23:284-7.
54. Conzelmann E, Sandhoff K. Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci. 1983;6:58-71.
55. M1-gangliosidosis. Ann Neurol. 2007;62:671-5.
56. M1-gangliosidosis. Glycoconjugate J. 1997;14:729-36.
57. M1-gangliosidosis model mice. Brain Dev. 2007; 29:210-6.
58. Ginalski K, Elofsson A, Fischer D, Rychlewski L. 3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics. 2003;19:1015-8.
59. Kajan L, Rychlewski L. Evaluation of 3D-Jury on CASP7 models. BMC Bioinformatics. 2007;8:304.
60. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and emprical binding free energy function. J Comput Chem. 1998;19:1639-62.
61. Case DA, Cheatham-III-TE, Darden T, et al. The Amber biomolecular simulations programs. J Comput Chem. 2005;26:1668-88.
62. a values. Proteins. 2005; 61:704-21.
63. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A. 2002;99:15428-33.
64. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D. Pharmacological enhancement of β-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem. 2004;279:13478-87.